DNA methylation in pulmonary fibrosis and lung cancer

ABSTRACT Introduction Pulmonary fibrosis is an age-related, progressive, and fatal disease with a median survival of 3–5 years after diagnosis; idiopathic pulmonary fibrosis (IPF) is the most common type. It is characterized by fibroblast proliferation and accumulation of excessive extracellular matrix. Patients with IPF are at increased risk for lung cancer. Epigenetic mechanisms are involved in lung fibrosis and cancer, and DNA methylation is critical in disease pathogenesis and progression. Therefore, studies of DNA methylation contribute to better understanding of the underlying mechanisms of these two respiratory diseases, and can offer novel diagnostic and treatment options. Areas covered This review discusses the latest advances in our understanding of epigenetic factors related to DNA methylation that impact development of lung cancer and pulmonary fibrosis, discusses the role of DNA methylation in promoting or inhibiting these diseases, and proposes its potential clinical significance in disease diagnosis and treatment. Expert opinion DNA methylation plays a critical role in lung cancer and fibrosis pathogenesis. DNA methylation offers a new biomarker for disease diagnosis or monitoring, and provides a new therapeutic target for treatment.

[1]  Yumei Fan,et al.  Latest progress on the molecular mechanisms of idiopathic pulmonary fibrosis , 2020, Molecular Biology Reports.

[2]  S. Pan,et al.  MAb NJ001 inhibits lung adenocarcinoma invasiveness by directly regulating TIMP‐3 promoter activity via FOXP1 binding sites , 2020, Thoracic cancer.

[3]  Y. Sanders.  New Clue: Prediction from Cell-Free DNA , 2020, Journal of clinical medicine.

[4]  M. Eccles,et al.  Promoter DNA Hypermethylation and Paradoxical Gene Activation. , 2020, Trends in cancer.

[5]  N. Zarovni,et al.  When Less Is More: Specific Capture and Analysis of Tumor Exosomes in Plasma Increases the Sensitivity of Liquid Biopsy for Comprehensive Detection of Multiple Androgen Receptor Phenotypes in Advanced Prostate Cancer Patients , 2020, Biomedicines.

[6]  Xiaorong Wu,et al.  DNMT1 promotes cell proliferation via methylating hMLH1 and hMSH2 promoters in EGFR-mutated non-small cell lung cancer. , 2020, Journal of biochemistry.

[7]  J. Herman,et al.  Ultrasensitive DNA hypermethylation detection using plasma for early detection of NSCLC: a study in Chinese patients with very small nodules , 2020, Clinical Epigenetics.

[8]  Y. Sanders,et al.  MeCP2 epigenetically regulates alpha‐smooth muscle actin in human lung fibroblasts , 2020, Journal of cellular biochemistry.

[9]  C. Guda,et al.  Global DNA Hypomethylation in Epithelial Ovarian Cancer: Passive Demethylation and Association with Genomic Instability , 2020, Cancers.

[10]  A. Kaneda,et al.  A low DNA methylation epigenotype in lung squamous cell carcinoma and its association with idiopathic pulmonary fibrosis and poorer prognosis , 2020, International journal of cancer.

[11]  R. Frazzi,et al.  Droplet digital PCR is a sensitive tool for the detection of TP53 deletions and point mutations in chronic lymphocytic leukaemia , 2020, British journal of haematology.

[12]  Yuan-Xiang Shi,et al.  Current Landscape of Epigenetics in Lung Cancer: Focus on the Mechanism and Application , 2019, Journal of oncology.

[13]  P. Ozretić,et al.  Promoter methylation status of ASC/TMS1/PYCARD is associated with decreased overall survival and TNM status in patients with early stage non-small cell lung cancer (NSCLC). , 2019, Translational lung cancer research.

[14]  J. Alcaraz,et al.  Epigenetic SMAD3 repression in tumor-associated fibroblasts impairs fibrosis and response to the antifibrotic drug nintedanib in lung squamous cell carcinoma. , 2019, Cancer research.

[15]  H. Shin,et al.  Global DNA Methylation Pattern of Fibroblasts in Idiopathic Pulmonary Fibrosis. , 2019, DNA and cell biology.

[16]  Matthew J. Meiners,et al.  H3K36me2 recruits DNMT3A and shapes the intergenic DNA methylation landscape , 2019, Nature.

[17]  Yuan Yuan,et al.  An inverse interaction between HOXA11 and HOXA11-AS is associated with cisplatin resistance in lung adenocarcinoma , 2019, Epigenetics.

[18]  M. Gonsebatt,et al.  Association of the Promoter Methylation and the rs12917 Polymorphism of MGMT with Formation of DNA Bulky Adducts and the Risk of Lung Cancer in Mexican Mestizo Population. , 2019, DNA and cell biology.

[19]  Yan Zhao,et al.  Silencing NID2 by DNA Hypermethylation Promotes Lung Cancer , 2019, Pathology & Oncology Research.

[20]  T. Kinoshita,et al.  Molecular Mechanisms of Pulmonary Fibrogenesis and Its Progression to Lung Cancer: A Review , 2019, International journal of molecular sciences.

[21]  Jixiang Wu,et al.  Inactivation of SMARCA2 by promoter hypermethylation drives lung cancer development. , 2019, Gene.

[22]  D. Weisenberger,et al.  The Roles of Human DNA Methyltransferases and Their Isoforms in Shaping the Epigenome , 2019, Genes.

[23]  G. Raghu,et al.  Idiopathic pulmonary fibrosis: unmasking cryptogenic environmental factors , 2019, European Respiratory Journal.

[24]  J. Cortijo,et al.  Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets , 2019, International journal of molecular sciences.

[25]  S. Patra,et al.  DNA methylation regulates Microtubule‐associated tumor suppressor 1 in human non‐small cell lung carcinoma , 2019, Experimental cell research.

[26]  Jia Cao,et al.  TMEM196 hypermethylation as a novel diagnostic and prognostic biomarker for lung cancer , 2018, Molecular carcinogenesis.

[27]  Longyang Jiang,et al.  High PITX1 expression in lung adenocarcinoma patients is associated with DNA methylation and poor prognosis. , 2018, Pathology, research and practice.

[28]  P. Micke,et al.  The Role of TGF-β Signaling in Lung Cancer Associated with Idiopathic Pulmonary Fibrosis , 2018, International journal of molecular sciences.

[29]  Y. Yen,et al.  Hypermethylation of CCND2 in Lung and Breast Cancer Is a Potential Biomarker and Drug Target , 2018, International journal of molecular sciences.

[30]  T. Brüning,et al.  Methylation of L1RE1, RARB, and RASSF1 function as possible biomarkers for the differential diagnosis of lung cancer , 2018, PloS one.

[31]  E. Bowman,et al.  HOXA9 methylation and blood vessel invasion in FFPE tissues for prognostic stratification of stage I lung adenocarcinoma patients. , 2018, Lung cancer.

[32]  S. Pradhan,et al.  Targeting the SET and RING-associated (SRA) domain of ubiquitin-like, PHD and ring finger–containing 1 (UHRF1) for anti-cancer drug development , 2018, Oncotarget.

[33]  Y. Chen,et al.  Methylation-mediated loss of SFRP2 enhances invasiveness of non–small cell lung cancer cells , 2018, Human & experimental toxicology.

[34]  Dan Han,et al.  5-aza-2′-deoxycytidine, a DNA methylation inhibitor, attenuates hyperoxia-induced lung fibrosis via re-expression of P16 in neonatal rats , 2017, Pediatric Research.

[35]  M. Kreuter,et al.  Patients with IPF and lung cancer: diagnosis and management. , 2017, The Lancet. Respiratory medicine.

[36]  O. Brand,et al.  Interplay between EZH2 and G9a Regulates CXCL10 Gene Repression in Idiopathic Pulmonary Fibrosis , 2017, American journal of respiratory cell and molecular biology.

[37]  M. Christmann,et al.  Epigenetic regulation of DNA repair genes and implications for tumor therapy. , 2017, Mutation research.

[38]  Lin Wang,et al.  DNA Methylation Analysis of the SHOX2 and RASSF1A Panel in Bronchoalveolar Lavage Fluid for Lung Cancer Diagnosis , 2017, Journal of Cancer.

[39]  M. Esteller,et al.  Lung cancer epigenetics: From knowledge to applications. , 2017, Seminars in cancer biology.

[40]  Chun Xing Li,et al.  DNA methylation regulated gene expression in organ fibrosis. , 2017, Biochimica et biophysica acta. Molecular basis of disease.

[41]  Vasilis Aidinis,et al.  Lung cancer in patients with idiopathic pulmonary fibrosis. , 2017, Pulmonary pharmacology & therapeutics.

[42]  B. Li,et al.  A regulatory circuit composed of DNA methyltransferases and receptor tyrosine kinases controls lung cancer cell aggressiveness , 2017, Oncogene.

[43]  J. Neuzil,et al.  Circulating epigenetic biomarkers in lung malignancies: From early diagnosis to therapy. , 2017, Lung cancer.

[44]  D. Weisenberger,et al.  DNA methylation aberrancies as a guide for surveillance and treatment of human cancers , 2017, Epigenetics.

[45]  Yaoyao Shi,et al.  Methylation analysis of SHOX2 and RASSF1A in bronchoalveolar lavage fluid for early lung cancer diagnosis. , 2017, Annals of diagnostic pathology.

[46]  Xiaodong Song,et al.  miR-30a as Potential Therapeutics by Targeting TET1 through Regulation of Drp-1 Promoter Hydroxymethylation in Idiopathic Pulmonary Fibrosis , 2017, International journal of molecular sciences.

[47]  Jhin Jieh Lim,et al.  Epigenetics in cancer stem cells , 2017, Molecular Cancer.

[48]  Jian-fei Song,et al.  Hypermethylation of ATP‐binding cassette B1 (ABCB1) multidrug resistance 1 (MDR1) is associated with cisplatin resistance in the A549 lung adenocarcinoma cell line , 2016, International journal of experimental pathology.

[49]  Liangfang Shen,et al.  Silencing of miR-1247 by DNA methylation promoted non-small-cell lung cancer cell invasion and migration by effects of STMN1 , 2016, OncoTargets and therapy.

[50]  S. O’Reilly,et al.  DNA methylation in fibrosis. , 2016, European journal of cell biology.

[51]  E. Lianidou,et al.  SOX17 promoter methylation in plasma circulating tumor DNA of patients with non-small cell lung cancer , 2016, Clinical chemistry and laboratory medicine.

[52]  G. Yüce,et al.  Lung cancer and epigenetic modifications , 2016 .

[53]  R. Shackelford,et al.  Epigenetics in non-small cell lung cancer: from basics to therapeutics. , 2016, Translational lung cancer research.

[54]  Antoni Rosell,et al.  A Novel Epigenetic Signature for Early Diagnosis in Lung Cancer , 2016, Clinical Cancer Research.

[55]  Deruo Liu,et al.  Promoter methylation of APC and RAR-β genes as prognostic markers in non-small cell lung cancer (NSCLC). , 2016, Experimental and molecular pathology.

[56]  G. Laurent,et al.  Epigenetic regulation of cyclooxygenase-2 by methylation of c8orf4 in pulmonary fibrosis , 2016, Clinical science.

[57]  Hong Wang,et al.  Real-time monitoring efficiency and toxicity of chemotherapy in patients with advanced lung cancer , 2015, Clinical Epigenetics.

[58]  B. Staitieh,et al.  TGF-β1 epigenetically modifies Thy-1 expression in primary lung fibroblasts. , 2015, American journal of physiology. Cell physiology.

[59]  Chen Wang,et al.  Methylation-mediated BMPER expression in fibroblast activation in vitro and lung fibrosis in mice in vivo , 2015, Scientific Reports.

[60]  J. Alcaraz,et al.  Aberrant DNA methylation in non-small cell lung cancer-associated fibroblasts , 2015, Carcinogenesis.

[61]  M. Wielscher,et al.  Diagnostic Performance of Plasma DNA Methylation Profiles in Lung Cancer, Pulmonary Fibrosis and COPD , 2015, EBioMedicine.

[62]  S. Clark,et al.  Methyl-CpG-binding domain proteins: readers of the epigenome. , 2015, Epigenomics.

[63]  P. Tschanter,et al.  5-azacytidine enhances efficacy of multiple chemotherapy drugs in AML and lung cancer with modulation of CpG methylation. , 2015, International journal of oncology.

[64]  N. Kaminski,et al.  Epigenetics in idiopathic pulmonary fibrosis. , 2015, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[65]  Avrum Spira,et al.  Relationship of DNA methylation and gene expression in idiopathic pulmonary fibrosis. , 2014, American journal of respiratory and critical care medicine.

[66]  Steven K. Huang,et al.  Lung Fibroblasts from Patients with Idiopathic Pulmonary Fibrosis Exhibit Genome-Wide Differences in DNA Methylation Compared to Fibroblasts from Nonfibrotic Lung , 2014, PloS one.

[67]  W. Coward,et al.  A central role for G9a and EZH2 in the epigenetic silencing of cyclooxygenase-2 in idiopathic pulmonary fibrosis , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[68]  L. Galluzzi,et al.  Systems biology of cisplatin resistance: past, present and future , 2014, Cell Death and Disease.

[69]  Yun Zheng,et al.  Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancer , 2014, Epigenetics.

[70]  P. Forde,et al.  New Strategies in Lung Cancer: Epigenetic Therapy for Non–Small Cell Lung Cancer , 2014, Clinical Cancer Research.

[71]  Jae Ho Lee,et al.  Lung cancer in patients with idiopathic pulmonary fibrosis: clinical characteristics and impact on survival. , 2013, Respiratory medicine.

[72]  Cheng Huang,et al.  The role of methyl-CpG binding protein 2 in liver fibrosis. , 2013, Toxicology.

[73]  V. Poletti,et al.  Idiopathic Pulmonary Fibrosis: Diagnosis and Prognostic Evaluation , 2013, Respiration.

[74]  D. Koh,et al.  The proto-oncoprotein FBI-1 interacts with MBD3 to recruit the Mi-2/NuRD-HDAC complex and BCoR and to silence p21WAF/CDKN1A by DNA methylation , 2013, Nucleic acids research.

[75]  M. Scharfe,et al.  Differential roles for MBD2 and MBD3 at methylated CpG islands, active promoters and binding to exon sequences , 2013, Nucleic acids research.

[76]  Xiangyu Zhang,et al.  Altered DNA methylation profile in idiopathic pulmonary fibrosis. , 2012, American journal of respiratory and critical care medicine.

[77]  R. Chen,et al.  5-Aza-2′-Deoxycytidine Improves the Sensitivity of Endometrial Cancer Cells to Progesterone Therapy , 2012, International Journal of Gynecologic Cancer.

[78]  Z. Yakhini,et al.  Global Methylation Patterns in Idiopathic Pulmonary Fibrosis , 2012, PloS one.

[79]  M. Selman,et al.  Hypermethylation‐Mediated Silencing of p14ARF in Fibroblasts from Idiopathic Pulmonary Fibrosis (IPF) , 2012, American journal of physiology. Lung cellular and molecular physiology.

[80]  A. Clarke,et al.  The Roles of the Methyl-CpG Binding Proteins in Cancer. , 2011, Genes & cancer.

[81]  T. Liloglou,et al.  UHRF1‐mediated tumor suppressor gene inactivation in nonsmall cell lung cancer , 2011, Cancer.

[82]  S. Duthie.  Epigenetic modifications and human pathologies: cancer and CVD , 2010, Proceedings of the Nutrition Society.

[83]  E. White,et al.  Hypermethylation of PTGER2 confers prostaglandin E2 resistance in fibrotic fibroblasts from humans and mice. , 2010, The American journal of pathology.

[84]  Biao Hu,et al.  Essential role of Mecp2 in the regulation of myofibroblast differentiation , 2010, The American journal of pathology.

[85]  W. Xiao,et al.  Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy , 2009, Current genomics.

[86]  G. Nuovo,et al.  Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis. , 2008, American journal of respiratory cell and molecular biology.

[87]  H. Hsu,et al.  Alteration of DNA methyltransferases contributes to 5'CpG methylation and poor prognosis in lung cancer. , 2007, Lung cancer.

[88]  J. Hagood,et al.  Enhanced myofibroblastic differentiation and survival in Thy-1(-) lung fibroblasts. , 2007, American journal of respiratory cell and molecular biology.

[89]  P. Barber,et al.  Smoking is associated with a decrease of O6‐alkylguanine‐DNA alkyltransferase activity in bronchial epithelial cells , 2006, International journal of cancer.

[90]  K. Robertson.  DNA methylation and human disease , 2005, Nature Reviews Genetics.

[91]  Li Yu,et al.  [DNA methylation and cancer]. , 2005, Zhonghua nei ke za zhi.

[92]  J. Herman,et al.  Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. , 2003, Cancer research.

[93]  S. Hirohashi,et al.  Heterogeneity in the modification and involvement of chromatin components of the CpG island of the silenced human CDH1 gene in cancer cells. , 2002, Nucleic acids research.

[94]  R. Roberts,et al.  Co‐operation and communication between the human maintenance and de novo DNA (cytosine‐5) methyltransferases , 2002, The EMBO journal.

[95]  Peter L. Jones,et al.  DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters , 2000, Nature Genetics.

[96]  D. Haber,et al.  DNA Methyltransferases Dnmt3a and Dnmt3b Are Essential for De Novo Methylation and Mammalian Development , 1999, Cell.

[97]  A. Bird,et al.  Identification and Characterization of a Family of Mammalian Methyl-CpG Binding Proteins , 1998, Molecular and Cellular Biology.

[98]  I. Waczulíková,et al.  The value of SHOX2 methylation test in peripheral blood samples used for the differential diagnosis of lung cancer and other lung disorders. , 2016, Neoplasma.

[99]  M. Metintaş,et al.  miRSNPs of miR1274 and miR3202 Genes that Target MeCP2 and DNMT3b Are Associated with Lung Cancer Risk: A Study Conducted on MassARRAY Genotyping. , 2016, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.

[100]  Ebru Ortaç Ersoy,et al.  [Lung cancer and epigenetic modifications]. , 2016, Tuberkuloz ve toraks.

[101]  Ping Xiao,et al.  Methylation of P16 in exhaled breath condensate for diagnosis of non-small cell lung cancer. , 2014, Lung cancer.

[102]  M. Grever,et al.  Phase I study of 5-aza-2′-deoxycytidine in combination with valproic acid in non-small-cell lung cancer , 2012, Cancer Chemotherapy and Pharmacology.

[103]  M. Selman,et al.  Hypermethylation-mediated silencing of p14 in fibroblasts from idiopathic pulmonary fibrosis , 2012 .

[104]  P. Codogno.  [Autophagy in cell survival and death]. , 2005, Journal de la Societe de biologie.